Screener
Eligibility screening
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
Sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD)Study detailsClinicalTrials.gov
5 US sites in GA, MD, NY, VA
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.